|
1. |
Familial thrombophilia and the prothrombin 20210A mutationassociation with increased thrombin generation and unusual thrombosis |
|
Blood Coagulation and Fibrinolysis,
Volume 10,
Issue 1,
1999,
Page 1-6
J. Eikelboom,
L. Ivey,
J. Ivey,
R. Baker,
Preview
|
PDF (326KB)
|
|
摘要:
The 20210A prothrombin mutation has recently been associated with an increased risk of venous thrombosis, but the mechanism of the increased thrombotic risk in affected persons has not been elucidated. We report on a thrombophilic family in which the proband presented with cerebral vein thrombosis and homozygosity for the 20210A prothrombin mutation as her only identifiable risk factor for venous thrombosis. Extended genotyping of family members revealed seven other affected, but asymptomatic, first-degree relatives (one A/A homozygote and six G/A heterozygotes). Plasma levels of prothrombin, prothrombin fragments 1+2 and thrombin-antithrombin complexes were highest in A/A homozygotes, intermediate in G/A heterozygotes and lowest in those with the G/G homozygous normal genotype, while D-dimer levels were elevated only in A/A homozygotes. Our results suggest that the 20210A prothrombin mutation is associated with activation of coagulation and increased thrombin generation, not only in patients with a past history of thrombosis but also in otherwise healthy asymptomatic persons. In a similar fashion to the homozygous factor V Leiden mutation, patients with the homozygous 20210A prothrombin mutation could be at highest risk of thrombosis, as suggested by our patient who presented with unusual thrombosis.
ISSN:0957-5235
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
Careful selection of sample dilution and factor‐V‐deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation |
|
Blood Coagulation and Fibrinolysis,
Volume 10,
Issue 1,
1999,
Page 7-18
H. de Ronde,
R. Bertina,
Preview
|
PDF (874KB)
|
|
摘要:
The aim of this study was to evaluate critically the recently modified activated-partial-thromboplastin-time (APTT)-based activated protein C (APC)-resistance tests, which are more specific for the factor V Leiden mutation than the first generation APC-resistance tests. The only modification to these tests is the predilution of the plasma sample in factor-V-deficient plasma. The intended effect of this predilution is to bring the concentrations of all clotting factors, except factor V, to the same normal levels. This, in principle, makes the tests also suitable for assaying the plasma of patients treated with oral anticoagulants and heparin, or of patients with a lupus anticoagulant. However, not every factor-V-deficient plasma is suitable for this application. Because the factor V: factor VIII ratio is important in establishing the APC ratio, the factor-V-deficient plasma should contain a sufficiently high factor VIII concentration. We also found that the optimal dilution to obtain the same APC ratios for patients, whether or not treated with coumarins or heparin, is not the same for each test or factor-V-deficient plasma. We compared two modified APTT-based APC-resistance tests (one developed in our laboratory and one commercial) with respect to their ability to discriminate between carriers and non-carriers of the factor V Leiden mutation. Both modified tests gave complete separation of carriers and non-carriers of the factor V Leiden mutation whether or not they are treated with anticoagulants. This makes these tests very suitable for routine screening.
ISSN:0957-5235
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
Acute effects of angiotensin II on fibrinolysis in healthy volunteers |
|
Blood Coagulation and Fibrinolysis,
Volume 10,
Issue 1,
1999,
Page 19-24
P. Larsson,
J. Schwieler,
N. Wallén,
P. Hjemdahl,
Preview
|
PDF (459KB)
|
|
摘要:
Recent studies have suggested that angiotensin II may inhibit fibrinolysis. In order to further test this hypothesis, we investigated the acute effects of angiotensin II (intravenous infusion of 10 ng/kg per min over 15–20 min) on fibrinolytic function in 18 healthy men. Time-controls (n= 11) and control experiments with a placebo infusion (n= 13) were also performed. The activities of plasmin activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA), as well as t-PA antigen levels, were determined in plasma before, during and 60 min after the infusion of angiotensin II. Angiotensin II caused a clear-cut elevation in blood pressure; heart rate and plasma noradrenaline levels tended to decrease during the infusion but increased afterwards, indicating reflexogenic adjustments. Plasma t-PA activity and antigen levels increased by 81±11 and 14±3%, respectively, during angiotensin II infusion (bothP< 0.001), whereas t-PA activity was unchanged and t-PA antigen decreased (P< 0.05) in placebo experiments. PAI-1 activity decreased similarly in time-controls and during angiotensin infusion (P< 0.001). Thus, short-term infusion of angiotensin II enhances fibrinolysis by elevating plasma t-PA. It is not clear whether this is a direct angiotensin-receptor-mediated effect or if it is related to the hemodynamic effects of the infusion.
ISSN:0957-5235
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
Performance of the platelet function analyser PFA‐100® in testing abnormalities of primary haemostasis |
|
Blood Coagulation and Fibrinolysis,
Volume 10,
Issue 1,
1999,
Page 25-32
P. Harrison,
M. Robinson,
I. Mackie,
J. Joseph,
S. McDonald,
R. Liesner,
G. Savidge,
J. Pasi,
S. Machin,
Preview
|
PDF (508KB)
|
|
摘要:
The PFA-100® device is a new instrument for the in-vitro testing of platelet function. Primary haemostasis is stimulated by recording the closure time taken for platelets to seal a 150 μm aperture in the centre of a membrane coated with collagen and either epinephrine or ADP. Patients with type 3 von Willebrand's disease (n= 4) all had infinitely prolonged closure times (> 200 s) with both types of cartridge. A patient with afibrinogenemia exhibited only slightly prolonged closure times of 111 and 166 s for the ADP and epinephrine membranes, respectively. Patients with Glanzmann's thrombasthenia (n= 6) and Bernard Soulier syndrome (n= 2) had grossly prolonged closure times (> 200 s) with both types of cartridges. These results confirmed that the PFA-100® system was highly dependent on normal von Willebrand factor, glycoprotein lb and glycoprotein IIb/IIIa levels but not on plasma fibrinogen. Patients with storage pool disease (n= 6) and Hermansky Pudlak syndrome (n= 7) had prolonged closure times with the epinephrine cartridge. There was no evidence of enhanced platelet function in patients with antiphospholipid syndrome, in sickle-cell disease or thalassemia. However, ingestion of aspirin resulted in a near consistent and significant prolongation of the closure time for the epinephrine cartridge but not for the ADP cartridge in both normal subjects and patients. The test offers a reliable, reproducible, rapid and simple means of assessing high-shear platelet function in vitro.
ISSN:0957-5235
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitoradvantages of administration by continuous infusion over bolus intermittent injections |
|
Blood Coagulation and Fibrinolysis,
Volume 10,
Issue 1,
1999,
Page 33-38
F. Scaraggi,
V. Mitrio,
R. Marino,
V. Speciale,
L. Bari,
M. Petronelli,
O. Schiraldi,
Preview
|
PDF (530KB)
|
|
摘要:
Recent studies have shown that treatment with a continuous infusion of recombinant activated factor VII (rFVIIa) is far more convenient than administration by bolus intermittent injections and may allow a substantial reduction in the dose. We present the case of a 26-year-old patient with hemophilia A, who had a high-titer inhibitor to both human and porcine factor VIII, and who had recently been admitted to hospital because of a bilateral severe ilio-psoas hematoma. Two subsequent courses of treatment with rFVIIa by bolus intermittent injection showed only a partial efficacy. A further administration of rFVIIa was therefore carried out using a continuous infusion regimen that proved to be fully efficacious. During the continuous infusion course levels of factor VII coagulant activity were in the range 18.2–5.2 U/ml, while the prothrombin time, expressed as an International Normalized Ratio, remained within the range 0.57–0.71. The continuous infusion, compared with the administration of the bolus intermittent infusion, reduced the amount of rFVIIa required by approximately 40–50%. Statistical analysis demonstrated that there was a strong positive correlation between the rate of infusion of rFVIIa and levels of factor VII coagulant activity (r= +0.941;P< 0.001), and a very significant negative correlation between levels of factor VII coagulant activity and prothrombin time values (r= −0.897;P< 0.001). In accordance with previous findings, our experience confirms that, when prolonged therapy is required, treatment with rFVIIa by continuous infusion is more convenient than administration of bolus intermittent injections, and may allow the saving of a large amount of drug. Moreover, we suggest potential additional advantages of the continuous infusion regimen over bolus intermittent injections, such as a better efficacy and a stronger correlation between prothrombin time and factor VII coagulant activity levels.
ISSN:0957-5235
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease |
|
Blood Coagulation and Fibrinolysis,
Volume 10,
Issue 1,
1999,
Page 39-39
M. Vargas,
I. Soto,
C. Pinto,
M. Urgelles,
A. Batalla,
J. Rodriguez-Reguero,
A. Cortina,
V. Alvarez,
E. Coto,
Preview
|
PDF (258KB)
|
|
摘要:
This study was performed in order to establish the role of the prothrombin 20210 G/A and factor V Leiden (R506Q) polymorphisms in the susceptibility to develop venous thromboembolism and early coronary artery disease (CAD). These polymorphisms were determined in 82 consecutive patients with venous thromboembolism, 175 male patients with early CAD, and 200 healthy controls from the same Caucasian population (Asturias, Northern Spain). DNA was amplified using polymerase chain reactions and digested with the appropriate restriction enzymes in order to define the prothrombin and factor V genotypes. The prevalence of the heterozygous for the prothrombin A allele was 3.5% in the general population and 15.8% in patients with venous thrombosis (P= 0.0007); the frequency was 4% in patients with early CAD. No sex-related differences in the prevalence of the A allele were observed, and the average age at the first venous thromboembolic event was similar between GG and AG patients. The frequency of carriers of the factor V Leiden polymorphism was 9.75% among patients with venous thromboembolism, compared with 3.5% among controls, and 3.4% in the patients with CAD. Our data showed an association between venous thromboembolism and the AG genotype at the prothrombin 20210 G/A polymorphism. This polymorphism was not related to an increased risk for early CAD in our population of male patients.
ISSN:0957-5235
出版商:OVID
年代:1999
数据来源: OVID
|
|